ACVR1C

So, yep, yep, you're absolutely right.

And then quickly, Roche last week, as I mentioned, deal with Rona, which was the second China to West licensing deal this year for an ALK7 targeting siRNA.

Now, that's a trend we've been following for some time now, right, Simone?

Yeah, we started to see this, I think, coming out of the China conference last year, and it taps back into my innovation theme here.

I think it's a very interesting development.

Yeah.

And just to add on to that, I think what I find quite fascinating in particular about ALK7 is that this is a target that is not a liver target, but this is an adipose tissue target.

So there is not only the biology of being able to knock down ALK7, but then you have to deliver it to the right tissue target.

No, very exciting time for that, for that growth opportunity.

But you've also got, you know, as you mentioned with 22, well, you know, I guess maybe 21 other clinical stage programs, you know, two that obviously I'm, I found a lot of interest in were the two obesity programs targeting inhibini and ALK7, the latter of which is the one that we talked about that is delivered directly to adipose tissue rather than to the liver.

But obviously, you know, Obesity is not exactly a, you know, pretty crowded space.

So what do you envision is the sort of the opportunity for these types of therapies in obesity? You know, where do you see them fitting in with relation to the incretins and oral therapies and other things that are clearly going to be on the market by the time, you know, these things are in late stage testing?

And so so that's that's just one example of how other therapies can be combined potentially with GLP ones.

You know, so we're going to see where this plays out.

You know, we need to treat a variety of patient populations with both inhibini and ALK7 to see where this plays out.

But early data suggests that some opportunities may be in diabetic patients.

The integration reduces coordinator burden and allows sponsors to accelerate data acquisition timelines.

And finally, Roche licensed an RNAi candidate targeting ALK7 from Rona Therapeutics for obesity under a deal worth up to 100 million US dollars upfront and up to 1.06 billion dollars in additional milestone payments.

ALK7, expressed in adipose tissue, reduces visceral and ectopic fat while preserving lean mass through direct tissue targeting rather than appetite suppression.

the mechanism positions it as potentially complementary to existing GLP-1 therapies.

And that's all for today's ACT Brief.